EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trials

Junki Mizusawa iD, Hioryuki Sato, Larry V Rubinstein, Takeo Fujiwara, Kan Yonemori, Akihiro Hirakawa

Cancer Medicine · 2023

DOI: 10.1002/cam4.6370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Junki Mizusawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics Section, Clinical Research Support Office, National Cancer Center Hospital/Biostatistics Division, Center for Research Administration &…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug-Related Side Effects and Adverse Reactions, Neoplasms, Racial Groups. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Racial differences have been reported in toxicity outcomes for anticancer drug treatments. However, these observations were often from studies with small sample sizes, and many only reported the maximum grade of toxicity and no longitudinal information. This current analysis aims to investigate racial differences in longitudinal toxicities using a large‐scale clinical trials database.

Methods

Early‐phase clinical trials sponsored by the Cancer Therapy Evaluation Program at the National Cancer Institute, USA, that evaluated cytotoxic drugs and molecularly targeted agents between March 2000 and December 2012 were studied. Race was categorized as White, Black or African‐American, and Asian. Each toxicity's grade prevalence, mean grade at each cycle, and time to develop grade 2 or higher toxicity was evaluated.

Results

In total, 25,442 patients from 697 trials were included in this study. The number of patients categorized as White, Black, and Asian designations was 22,756 (89%), 1874 (7%), and 812 (3%), respectively. Notable findings include the rate of any grade of diarrhea in Black people was 26% and 21% lower than that of White and Asian people. The median time to the first grade 2 or higher event was 6 cycles in White people, 8 in Black people, and 6 in Asian people. The rate of any grade hyperglycemia was significantly higher in Asian people.

Conclusions

Although we identified several racial differences in longitudinal toxicities, most were of generally lower grade. Further study is needed to clarify the cause of racial differences in treatment‐associated toxicities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsNeoplasmsRacial GroupsFemaleHumansMaleBlack or African AmericanClinical Trials as TopicLongitudinal StudiesWhiteAsian

Stichwörter der Autor:innen

cancer chemotherapylongitudinal toxicityracial differences

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Biostatistics Section, Clinical Research Support Office, National Cancer Center Hospital/Biostatistics Division, Center for Research Administration & Support, National Cancer Center, Tokyo, Japan.
  • Department of Global Health Promotion, Tokyo Medical and Dental University, Tokyo, Japan.
  • Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
  • Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Rockville, Maryland, USA.
  • Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Junki Mizusawa

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Mizusawa, J., Sato, H., Rubinstein, L. V., Fujiwara, T., Yonemori, K., & Hirakawa, A. (2023). Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trials. Cancer Medicine. https://doi.org/10.1002/cam4.6370

Vancouver

Mizusawa J, Sato H, Rubinstein LV, Fujiwara T, Yonemori K, Hirakawa A. Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trials. Cancer Medicine. 2023. doi:10.1002/cam4.6370

BibTeX
@article{Mizusawa2023,
  author = {Mizusawa, Junki and Sato, Hioryuki and Rubinstein, Larry V and Fujiwara, Takeo and Yonemori, Kan and Hirakawa, Akihiro},
  title = {Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trials},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6370}
}
Kostenlos starten →